Study maps how semaglutide signals in brainstem neurons to drive weight loss

A paper published in Nature Metabolism in June 2026 describes how semaglutide (sold as Ozempic, Wegovy and Rybelsus) signals inside GLP-1 receptor-expressing neurons in the brainstem, and reports that disrupting that signaling removes the drug's weight-loss effect in the models studied ^[1].

The neurons sit in the area postrema, part of the hindbrain, which the paper calls the primary site of semaglutide's action in the brain ^[1]. GLP-1 receptors have long been described as Gs-coupled receptors, meaning they act through a particular G protein inside cells. The new work finds that semaglutide engages both Gs- and Gq-dependent signaling in these area postrema neurons and drives different levels of activation across distinct clusters of those neurons ^[1].

The paper focuses on cyclic adenosine monophosphate, or cAMP, a messenger molecule inside cells. Semaglutide produced graded increases in cAMP in area postrema neurons through the Gs pathway, according to the abstract ^[1]. Blocking phosphodiesterase 4 (PDE4), the enzyme that breaks cAMP down, made those cAMP responses larger and longer lasting ^[1]. When the researchers disrupted Gs or cAMP signaling in these neurons, semaglutide-induced weight loss and downstream activation across the brain were abolished ^[1].

The paper's figure captions add detail. Local disruption of Gs signaling in the dorsal vagal complex impaired energy balance and semaglutide-induced weight loss ^[1]. A separate population of neurons, labeled elPBN, was rapidly recruited after semaglutide was given peripherally and was required for semaglutide-induced conditioned taste aversion and weight loss in the models used ^[1]. Gs and Gq signaling pathways shaped feeding and body weight regulation in different ways ^[1].

Only the abstract and figure captions are publicly available; the full article sits behind a subscription ^[1]. The paper reports no human data, and the abstract does not list doses, human effect sizes, or the specific animal species used. This is basic science about mechanism rather than a clinical trial.

Why it matters for patients

The findings describe, at the level of individual cells, the pathway that appears to connect semaglutide binding in the hindbrain to reduced food intake and weight loss ^[1]. They may also help explain why the same drug can produce unwanted effects. The paper links one set of hindbrain neurons to conditioned taste aversion, a laboratory measure of aversion, and reports that those neurons were required both for that response and for weight loss in the models studied ^[1]. Whether that aversion circuit is the same one behind nausea in people is not established by this paper. The abstract notes that the work "provid[es] avenues for improving obesity therapeutics," suggesting the goal of separating beneficial effects from unwanted ones is a research direction, not something demonstrated here ^[1].

Nothing in this paper changes what is currently known about how these medicines are prescribed or how they are dosed. It reports no comparison of semaglutide with tirzepatide (Mounjaro, Zepbound) or orforglipron (Foundayo) ^[1].

What happens next

The paper does not announce any follow-up clinical study or give a timeline for future work, and no plans to test PDE4 inhibition or Gq signaling approaches in people are disclosed in it ^[1]. The authors state that source data are provided with the paper and that additional data are available on request from the corresponding authors ^[1]. Whether these signaling details can be turned into treatments that work better, or cause fewer side effects, in humans has not yet been reported.